Skip to main content
. 2021 Jan 18;7:632434. doi: 10.3389/fcvm.2020.632434

Table 3.

Clinical and echocardiographic characteristics of patients with COVID-19 according to disease severity.

Disease severity
Variables All patients (n = 132) Moderate (n = 50) Severe (n = 35) Critical (n = 47) p-value
Clinical characteristics
Age, years 61 ± 13 59 ± 12 62 ± 15 63 ± 12 0.241
Male, n (%) 68 (51.5%) 20 (40.0%) 19 (54.3%) 29 (61.7%) 0.093
Body mass index, kg/m2 23.6 ± 2.9 23.6 ± 2.6 23.4 ± 3.0 23.9 ± 3.2 0.810
Heart rate, beats/min 91 ± 17 90 ± 16 88 ± 15 94 ± 19 0.216
Respiratory rate, breaths/min 25 ± 6 24 ± 6 24 ± 5 25 ± 7 0.707
SBP, mm Hg 134 ± 18 134 ± 17 133 ± 20 131 ± 17 0.742
DBP, mm Hg 81 ± 12 82 ± 10 81 ± 14 80 ± 12 0.767
Left heart
LA dimension, mm 34.3 ± 5.4 34.3 ± 4.9 35.2 ± 4.7 34.2 ± 6.5 0.466
LV dimension, mm 45.5 ± 4.9 44.9 ± 4.6 46.4 ± 4.8 45.8 ± 5.1 0.526
IVS, mm 9.6 ± 1.3 9.7 ± 1.1 9.6 ± 1.9 9.6 ± 1.0 0.629
PW, mm 8.8 ± 1.9 9.2 ± 1.1 8.2 ± 2.7* 9.0 ± 1.7 0.049
LVM, g 144.3 ± 36.1 143.7 ± 35.6 148.0 ± 40.9 144.7 ± 33.6 0.861
DT, ms 204.4 ± 53.7 209.3 ± 60.4 190.0 ± 48.8 209.8 ± 46.5 0.176
E/A ratio 0.8 (0.7, 1.1) 0.8 (0.7, 1.1) 0.9 (0.7, 1.3) 0.8 (0.7, 1.0) 0.515
E/e′ ratio 8.4 (6.8, 10.6) 8.4 (6.5, 10.0) 8.8 (6.3, 10.6) 8.0 (6.9, 10.9) 0.891
LVEDVI, ml/m2 52.2 ± 16.1 55.0 ± 15.6 53.0 ± 17.5 48.9 ± 14.4 0.321
LVESVI, ml/m2 17.5 (15.2, 22.9) 17.5 (15.2, 22.8) 18.6 (15.8, 24.2) 16.2 (13.8, 23.1) 0.724
LVEF, % 62.8 ± 6.9 63.4 ± 7.7 62.5 ± 7.4 62.9 ± 5.8 0.882
LV GLS4CH, % 18.9 (16.8, 20.9) 20.1 (18.2, 22.0) 19.0 (17.3, 21.9) 17.0 (15.7, 18.6)*# <0.001
LAS-peak, % 33.7 ± 7.6 31.9 ± 7.9 35.8 ± 8.1 32.0 ± 10.2 0.146
Moderate-severe MR, n (%) 2 (1.5%) 0 (0) 0 (0) 2 (4.3%) 0.090
Right heart
RA dimension, mm 35.5 ± 4.6 34.7 ± 4.9 36.4 ± 3.4 35.9 ± 5.1 0.209
RV dimension, mm 34.0 (30.6, 36.4) 33.3 (29.8, 35.8) 34.4 (32.4, 36.6) 34.0 (30.7, 36.6) 0.485
TAPSE, mm 22.2 ± 3.8 22.8 ± 3.8 22.6 ± 3.5 20.8 ± 3.7*# 0.019
RVFAC, % 47.2 (41.6, 51.2) 49.3 (42.0, 52.2) 45.5 (40.8, 51.2) 46.9 (40.9, 50.3) 0.255
S′, cm/s 13.3 (11.9, 15.0) 14.0 (12.0, 15.0) 14.0 (12.0, 16.4) 12.9 (11.0, 15.0) 0.301
RV FWLS, % 22.7 (19.2, 25.6) 23.9 (20.1, 26.2) 23.6 (19.8, 26.1) 20.2 (18.1, 24.0)*# 0.015
Moderate-severe TR, n (%) 4 (3.0%) 0 (0) 0 (0) 4 (8.5%) 0.016
PASP, mm Hg 36 ± 14 30 ± 11 39 ± 14* 39 ± 15* 0.037
Prognosis
Discharge, n (%) 113 (85.6%) 50 (100.0%) 33 (97.1%) 30 (62.5%)*# <0.001
Death, n (%) 19 (14.4%) 0 (0) 1 (2.9%) 18 (37.5%)*# <0.001

Values are mean ± SD, n (%), median (interquartile range). *P < 0.05, severe or critical vs. moderate; #P < 0.05, critical vs. severe. COVID-19, coronavirus disease 2019; DBP, diastolic blood pressure; DT, peak E deceleration time of mitral inflow; IVS., interventricular septum; LA, left atrial; LAS, left atrial strain; LV, left ventricular; LV GLS4CH, left ventricular global longitudinal strain derived from the apical four-chamber view; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end systolic volume index; LVM, left ventricular mass; MR, mitral regurgitation; PASP, pulmonary artery systolic pressure; PW, posterior wall of left ventricle; RA, right atrial; RV, right ventricular; RV FWLS, right ventricular free wall longitudinal strain; RVFAC, RV fractional area change; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation. LV GLS4CH and RV FWLS values are absolute values.